Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALONX.PA
- Price
- -
- Stock movement up
- +0.00 (0.74%)
- Company name
- Onxeo SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Pharmaceuticals
- Market cap
- 30.17M
- Ent value
- 36.40M
- Price/Sales
- 6.14
- Price/Book
- 1.35
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 0.46
- PEG
- -
- EPS growth
- -31.37%
- 1 year return
- -13.38%
- 3 year return
- -28.37%
- 5 year return
- -25.41%
- 10 year return
- -23.44%
Last updated: 2024-12-17
DIVIDENDS
ALONX.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.14 |
| Price to Book | 1.35 |
| EV to Sales | 7.41 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 110.93M |
| EPS (TTM) | -0.19 |
| FCF per share (TTM) | -0.04 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.92M |
| Gross profit (TTM) | 4.22M |
| Operating income (TTM) | -17.32M |
| Net income (TTM) | -20.73M |
| EPS (TTM) | -0.19 |
| EPS (1y forward) | 0.59 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 85.76% |
| Operating margin (TTM) | -352.38% |
| Profit margin (TTM) | -421.62% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 14.59M |
| Net receivables | 1.47M |
| Total current assets | 20.58M |
| Goodwill | 18.26M |
| Intangible assets | 2.47M |
| Property, plant and equipment | 0.00 |
| Total assets | 43.09M |
| Accounts payable | 3.45M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 7.15M |
| Total liabilities | 20.82M |
| Shareholder's equity | 22.27M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -4.09M |
| Capital expenditures (TTM) | 136.50K |
| Free cash flow (TTM) | -4.22M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -93.07% |
| Return on Assets | -48.11% |
| Return on Invested Capital | -68.24% |
| Cash Return on Invested Capital | -13.91% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ALONX.PA | S&P500 | |
| Current price drop from All-time high | -98.02% | -10.01% |
| Highest price drop | -99.05% | -56.47% |
| Date of highest drop | 29 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -70.53% | -11.07% |
| Avg time to new high | 373 days | 12 days |
| Max time to new high | 4211 days | 1805 days |
COMPANY DETAILS
Marketcap
30.17M
Marketcap category
Small-cap
Description
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France.
Employees
25
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found